RE:Pfizer turns over Bravencio to Merck. Along with Pfizer wanting to avoid potential antitrust issues on the acquisition of Seagen, by divesting in Bavencio (avelumab), Pfizer is developing its own PD-1 immune checkpoint inhibitor - sasanlimab, which can be administered subqutaneously (subQ). Roche's (atezolizumab)Tecentriq and Merck's (pembrolizumab) Keytruda have also developed their own subQ immune checkpoint inhbitors.
So still Merck, Roche and Pfizer, notwithstanding today's development. Pfizer, Merck and Roche's antibody drug conjugates (ADC) are all able to benefit from the addition of ONCY's pelareorep in combination with immune checkpoint inhibitors.